For patients with an A1C of 6.5% to 7.5%, metformin is the preferred initial agent, with GLP-1 receptor agonists, dipeptidyl-peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), or an alpha-glucosidase inhibitor listed as viable alternatives
Posibles beneficios renales : Evidencia emergente, incluido el estudio FLOW con semaglutida, sugiere efectos protectores sobre la funcin renal en personas con enfermedad renal crnica y diabetes tipo 2
Why does this matter practically
The best time to take your GLP-1 injection is whichever time you can maintain consistently week after week
Better absorbed on an empty stomach
Researchers examine how this multi-receptor engagement may influence nutrient signaling, energy expenditure, and hormonal coordination in experimental systems